The recent development of immune checkpoint inhibitors and the corresponding efficacy shown by inhibitors of the CTLA-4/B7 [1] and PD-1/PD-L1 checkpoints [2–7] in multiple tumour types has resulted in substantial investment by the pharmaceutical industry in clinical development of immunotherapeutics across tumour types and indications. This evidence concerns the gene PDCD1 and neoplasm.